Analyst Reco. TG Therapeutics, Inc.

Equities

TGTX

US88322Q1085

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
16.3 ^USD	-3.49%		-2.45%	-4.57%

May. 01	Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts	MT
May. 01	Transcript : TG Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

TG Therapeutics Wins Veterans Affairs Contract for Multiple Sclerosis Drug Briumvi	Apr. 18	MT
Goldman Sachs Raises Price Target on TG Therapeutics to $13 From $12, Maintains Neutral Rating	Feb. 29	MT
B. Riley Adjusts Price Target on TG Therapeutics to $29 From $24, Maintains Buy Rating	Feb. 05	MT
HC Wainwright Adjusts TG Therapeutics Price Target to $45 From $41, Maintains Buy Rating	Jan. 11	MT
B. Riley Adjusts Price Target on TG Therapeutics to $24 From $32, Keeps Buy Rating	23-10-20	MT
JPMorgan Cuts TG Therapeutics Price Target to $22 From $34, Maintains Overweight Rating	23-08-07	MT
Goldman Sachs Upgrades TG Therapeutics to Neutral From Sell, Adjusts Price Target to $12 From $16	23-08-02	MT
B. Riley Lowers TG Therapeutics' PT to $32 From $42 After Lower-Than-Expected Q2 Results, Keeps Buy Rating	23-08-02	MT
HC Wainwright Adjusts TG Therapeutics' Price Target to $41 From $34, Keeps Buy Rating	23-08-01	MT
Goldman Sachs Adjusts TG Therapeutics' Price Target to $16 From $10, Keeps Sell Rating	23-07-24	MT
Ladenburg Thalmann Raises Price Target on TG Therapeutics to $37.50 From $26, Maintains Buy Rating	23-05-02	MT
B. Riley Raises TG Therapeutics' Price Target to $42 From $39 After 'Strong' Q1 Results, Keeps Buy Rating	23-05-02	MT
HC Wainwright Adjusts Price Target on TG Therapeutics to $28 From $24, Reiterates Buy Rating	23-04-14	MT
B. Riley Raises TG Therapeutics' Price Target to $39 From $23, Keeps Buy Rating	23-04-11	MT
Cantor Fitzgerald Raises Price Target on TG Therapeutics to $24 From $18, Maintains Overweight Rating	23-02-07	MT
Evercore ISI Adjusts Price Target on TG Therapeutics to $25 From $16, Maintains Outperform Rating	23-01-24	MT
Evercore ISI Adjusts Price Target on TG Therapeutics to $16 From $11, Maintains Outperform Rating	22-12-30	MT
Goldman Sachs Adjusts Price Target on TG Therapeutics to $6 From $4, Maintains Sell Rating	22-12-30	MT
B. Riley Boosts Price Target on TG Therapeutics to $23 From $17, Keeps Buy Rating	22-12-30	MT
BofA Raises Price Target on TG Therapeutics to $6 From $5, Maintains Underperform Rating	22-12-29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. TG Therapeutics, Inc.

Equities

TGTX

US88322Q1085

Analyst Reco.

Filters